Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Equity Ratio (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Equity Ratio for 15 consecutive years, with 0.32 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 15.02% to 0.32 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.32, a 15.02% increase, with the full-year FY2024 number at 0.04, down 110.27% from a year prior.
  • Equity Ratio was 0.32 for Q3 2025 at NovaBay Pharmaceuticals, down from 0.61 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.82 in Q2 2021 to a low of 9.64 in Q4 2022.
  • A 5-year average of 0.06 and a median of 0.55 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: soared 2218.94% in 2021, then plummeted 2373.56% in 2022.
  • NovaBay Pharmaceuticals' Equity Ratio stood at 0.42 in 2021, then tumbled by 2373.56% to 9.64 in 2022, then surged by 103.8% to 0.37 in 2023, then tumbled by 110.27% to 0.04 in 2024, then soared by 943.91% to 0.32 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Equity Ratio are 0.32 (Q3 2025), 0.61 (Q2 2025), and 0.62 (Q1 2025).